Clinical Trial Update: Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 study assessing whether AZD1656 alters the pharmacokinetics of sitagliptin in adults with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AZD1656
• Sitagliptin (sitagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED